Ergomed plc Issue of shares (5897T)
04 July 2018 - 8:11PM
UK Regulatory
TIDMERGO
RNS Number : 5897T
Ergomed plc
04 July 2018
PRESS RELEASE
Ergomed Issues 2017 Further Consideration Shares to Former
Shareholders of PSR Group BV
London, UK - 4 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or
the "Company") a company focused on providing specialised services
to the pharmaceutical industry, today announces that the conditions
for the issue of 345 additional new ordinary shares of 1p each in
the Company to former shareholders of PSR Group BV have been
satisfied ("2017 Further Consideration Shares").
Ergomed has approved the allotment and issue of the 2017 Further
Consideration Shares as part of the contingent consideration for
the acquisition of PSR, announced on 28 September 2017. Under the
terms of this deal, Ergomed acquired 100 per cent of the issued
share capital of PSR for consideration of up to EUR5.7 million
(GBP5.0 million), including contingent consideration based on the
achievement of EBITDA targets for 2017, 2018 and 2019 of up to an
aggregate further EUR2.6 million (GBP2.2 million). The contingent
consideration (earn-out) is satisfied 80% in cash and 20% in new
Ergomed Ordinary Shares.
Application has been made to the London Stock Exchange for 345
Ordinary Shares to be admitted to trading on AIM ('Admission'). It
is expected that Admission will occur at 8:00 a.m. on 9 July 2018.
The Ordinary Shares will rank pari passu with the existing ordinary
shares in the Company.
Following Admission, the Company's enlarged issued share capital
and total number of voting rights will be 44,858,947 Ordinary
Shares.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503 205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0) 20 7496 3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709
UK enquiries 5700
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Ivar Milligan / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEGMGGNGDVGRZM
(END) Dow Jones Newswires
July 04, 2018 06:11 ET (10:11 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024